FDA chief confirms mifepristone review but 'no plans' to change access

Drug Safety Review - The Health and Human Services Secretary requested a review of data on methapristone (abortion pill) [1] - The review is ongoing as part of a risk evaluation and mitigation strategy (REMS) commitment [2] - The review includes examining self-reported data in the adverse event reporting database [2] - The review also considers studies suggesting potential safety signals in large administrative databases, such as drug-drug interactions [3] Access to Medication - The company has no plans to change access to methapristone [3]